Boston Scientific Corp (BSX) Stock Price & Analysis
Boston Scientific Corp (BSX) rose 1.54% to USD 44.25 as of July 25, 2026 at 01:43 UTC, according to Nexqual real-time market data.
BSX last closed at USD 43.58; the session ranged USD 43.74–44.71 on volume of 17,310,420 shares. Market capitalization is $65.77B, with a 52-week range of USD 42.2–109.5 (NYQ). Source: Nexqual, July 25, 2026 at 01:43 UTC.
Key Statistics (as of July 25, 2026 at 01:43 UTC)
| Price | USD 44.25 |
|---|---|
| Change | ▲ 1.54% (up) |
| Previous Close | USD 43.58 |
| Open | USD 43.97 |
| Day Range | USD 43.74 – 44.71 |
| 52-Week Range | USD 42.2 – 109.5 |
| Volume | 17,310,420 shares |
| Market Cap | $65.77B |
| Exchange | NYQ |
Technical Analysis (BSX)
Nexqual's technical model rates BSX "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 01:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.78 (neutral) |
| vs SMA50 | Below (USD 47.45) |
| MACD | -1.05 (negative) |
Earnings (BSX)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.83 |
| Revenue Estimate | $5.37B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.8 vs est 0.79 ▲ beat |
| 2025-12-31 | USD 0.8 vs est 0.78 ▲ beat |
| 2025-09-30 | USD 0.75 vs est 0.71 ▲ beat |
| 2025-06-30 | USD 0.75 vs est 0.73 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:43 UTC.
Financials & Fundamentals (BSX)
| Total Revenue | $20.61B |
|---|---|
| Revenue Growth (YoY) | +11.60% |
| Gross Margin | +68.94% |
| Operating Margin | +20.60% |
| Profit Margin | +17.29% |
| ROE | +14.66% |
| Debt / Equity | 42.25 |
| Current Ratio | 1.9 |
| Total Cash | $1.45B |
| Total Debt | $11.03B |
| Free Cash Flow | $2.81B |
Source: Nexqual, July 25, 2026 at 01:43 UTC.
Ownership (BSX)
| Insider Ownership | +0.23% |
|---|---|
| Institutional Ownership | +93.79% |
| Shares Outstanding | 1.49B |
| Float | 1.48B |
| Short % of Float | +1.88% |
Source: Nexqual, July 25, 2026 at 01:43 UTC.
From Boston Scientific Corp's Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
- The company operates in two segments, MedSurg and Cardiovascular.
- In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MDT | Medtronic plc. | USD 83.21 | ▲ 1.61% |
| SYK | Stryker Corporation | USD 330.25 | ▲ 6.79% |
| BAX | Baxter International Inc. | USD 22.4 | ▲ 3.04% |
| EW | Edwards Lifesciences Corporatio | USD 82.63 | ▼ 2.06% |
| BDX | Becton, Dickinson and Company | USD 156.36 | ▲ 2.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:43 UTC. This page is informational and not investment advice.